arrow
I

Isabel Poschke

german cancer research center
H指数:33
被引数:4,253

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells

T细胞免疫监测:定量和表征人抗原特异性T细胞的传统方法与新方法的比较分析

2026-10-060
PRE
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial

IDH1突变疫苗在新诊断星形细胞瘤中的应用:多中心、单臂、开放标签、首次人体1期NOA16试验的最终分析

2026-07-010
OAAI
Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoire

小鼠胰腺肿瘤中T细胞浸润的剖析揭示了广泛的、多样的肿瘤反应性T细胞库

2026-04-100
OA
Multimodality mapping of immunotherapy distribution as a predictive marker in glioma

免疫疗法分布的多模态映射作为神经胶质瘤的预测标记

2025-12-310
PRE
Multimodality mapping of immunotherapy distribution as a prognostic marker in glioma

多模态成像示踪免疫治疗分布作为胶质瘤的预后标志物

2025-11-010
OAAI
MODULATION OF THE INTRATUMORAL IMMUNE MICROENVIRONMENT BY LOCAL THERAPY WITH NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中,通过用HER2-TARGETED嵌合抗原受体工程化的自然杀伤细胞局部治疗与全身ANTI-PD-1检查点抑制相结合来调节肿瘤内免疫微环境

2024-11-110
PRE
A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中重复颅内注射单独使用HER2-TARGETED嵌合抗原受体并结合全身ANTI-PD-1检查点抑制的自然杀伤细胞

2024-10-170
PRE
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
2024-01-043
OAAI
Transcriptome-based identification of tumor-reactive and bystander CD8+ T cell receptor clonotypes in human pancreatic cancer

基于转录组的人胰腺癌中肿瘤反应性和旁观者CD8 T细胞受体克隆型的鉴定

2023-11-156
PRE
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
2023-10-192
OAAI
A H3K27M-targeted vaccine in adults with diffuse midline glioma
2023-09-2126
OAAI